Flerie invests in product development and commercial growth companies primarily in drug development and associated tools and services. Headquartered in Stockholm Flerie invests in Europe, USA and Israel and has representatives in several European cities.
Extern länk för Flerie
Skeppsbron 16
Stockholm, SE
2 Royal College Street
London, NW1 0NH, GB
Flerie omdelade detta
Landmark Stockholm3 multi-ethnical trial, published in top-ranked Journal of Clinical Oncology, demonstrates the utility and generalizability of Stockholm3 in reducing unneeded biopsies and detecting prostate cancer in Asian, Black, Hispanic, and White men, representing an important improvement in the harm-benefit tradeoffs in prostate cancer detection. #urology #stockholm3 #prostatecancer #healthdisparities https://lnkd.in/dw-JqiED
We are pleased to share that Mendus AB has today announced a collaboration with Institut Bergonié. Ilixadencel will be studied as part of the REGOMUNE trial in soft tissue sarcomas in combination with regorafenib and avelumab.
We are excited to announce the collaboration with Institut Bergonié to study Mendus AB intratumoral immune primer #ilixadencel in soft tissue sarcomas as part of the #REGOMUNEtrial. For more details, please visit https://lnkd.in/eBbHJ2gH #ChangingTheCourseOfCancerTreatment
Flerie has published its Q2 2024 interim report in both English and Swedish. Please feel free to register for the Q2 report presentation and Q&A at 14:00 CET via this link, if you have not done so already: https://lnkd.in/dDKKGxaP
Invitation to presentation and Q&A of Flerie’s Q2 2024 interim report Date and time: Wednesday July 17 at 14:00 CEST
Flerie's monthly Net Asset Value (NAV) table below details our diversified portfolio across our segments. On the 30 June 2024 our NAV was SEK 4.38 billion and 0.561 SEK per share. The share price represented a discount to NAV of 15.9%. With a healthy cash balance Flerie will be able to continue building long-term value as we have done for the past 13 years prior to listing. See https://lnkd.in/eHE3K_GP.
Welcome to join us via the live broadcast for tomorrow's bell-ringing ceremony at Nasdaq. The broadcast starts on June 27th at 08:45 (CEST). https://lnkd.in/g46f4HPb
Today, Flerie hosted an investor presentation where we described our investment model and portfolio strategy. Use the link below to access the full recording of the presentation and the Q&A session, where Ted Fjällman, Cecilia Schéele, Mark Quick and Karl Elmqvist shared their knowledge and insights. Link to today's presentations: https://lnkd.in/dRMXcd2m
Join us for Flerie's investor presentation tomorrow. Register here: https://lnkd.in/dTEjPCMY We are delighted to invite you to Flerie's upcoming investor presentation in Stockholm, Sweden on June 19, 2024, from 09:00 to 09:45 CET. Agenda 09.00 Webcast starts Flerie as a listed company – purpose and potential | Ted Fjällman, CEO Flerie’s product development strategy explained | Karl Elmqvist, Investment Manager Flerie’s commercial growth strategy explained | Mark Quick, Partner Continuous and active value creation in the portfolio companies | Cecilia Schéele, CFO Concluding remarks | Ted Fjällman, CEO Time for questions | Paula Andersson, Q&A Moderator 09.45 End of webcast
We are pleased to invite you to Flerie’s upcoming investor presentation in Stockholm, Sweden on June 19, 2024 at 09.00-09.45 CET. The Management team will be available to answer questions from the audience on site and via webcast. Please use the following link för registration: https://lnkd.in/dTEjPCMY
We are pleased to share our CEO Dr Ted Fjällman's insightful presentation from Redeye Transactions last week. The presentation is in Swedish. https://lnkd.in/dT3zc-u9